Search company, investor...

AlphaVax

alphavax.com

Founded Year

1998

Stage

Series E | Alive

Total Raised

$31.9M

Valuation

$0000 

Last Raised

$12.7M | 16 yrs ago

About AlphaVax

AlphaVax focuses on vaccine development that ranges from a wide range of infections to cancer. Its technology is also used in veterinary vaccines.

Headquarters Location

2 Triangle Drive

Durham, North Carolina, 27709,

United States

800-658-2849

Missing: AlphaVax's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: AlphaVax's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing AlphaVax

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

AlphaVax is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

AlphaVax Patents

AlphaVax has filed 1 patent.

The 3 most popular patent topics include:

  • Biotechnology
  • Animal virology
  • Immunology
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/11/2016

2/25/2020

Molecular biology, Virus families, Virology, Animal virology, Vaccines

Grant

Application Date

8/11/2016

Grant Date

2/25/2020

Title

Related Topics

Molecular biology, Virus families, Virology, Animal virology, Vaccines

Status

Grant

Latest AlphaVax News

Global HIV Vaccines Market Research Report to 2027 - Featuring AlphaVax, Crucell and Novartis Among Others - ResearchAndMarkets.com

Feb 4, 2022

February 04, 2022 12:25 PM Eastern Standard Time The Global HIV Vaccines Market size was estimated at USD 252.89 million in 2020 and expected to reach USD 350.76 million in 2021, at a CAGR 39.13% to reach USD 2,552.37 million by 2027. The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2027 are considered the forecast period. Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period. FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the HIV Vaccines Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape. Market Share Analysis: The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits. The report provides insights on the following pointers: 1. Market Penetration: Provides comprehensive information on the market offered by the key players 2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets 3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players 5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments The report answers questions such as: 1. What is the market size and forecast of the Global HIV Vaccines Market? 2. What are the inhibiting factors and impact of COVID-19 shaping the Global HIV Vaccines Market during the forecast period? 3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global HIV Vaccines Market? 4. What is the competitive strategic window for opportunities in the Global HIV Vaccines Market? 5. What are the technology trends and regulatory frameworks in the Global HIV Vaccines Market? 6. What is the market share of the leading vendors in the Global HIV Vaccines Market? 7. What modes and strategic moves are considered suitable for entering the Global HIV Vaccines Market? Market Dynamics

AlphaVax Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

AlphaVax Rank

AlphaVax Frequently Asked Questions (FAQ)

  • When was AlphaVax founded?

    AlphaVax was founded in 1998.

  • Where is AlphaVax's headquarters?

    AlphaVax's headquarters is located at 2 Triangle Drive, Durham.

  • What is AlphaVax's latest funding round?

    AlphaVax's latest funding round is Series E.

  • How much did AlphaVax raise?

    AlphaVax raised a total of $31.9M.

  • Who are the investors of AlphaVax?

    Investors of AlphaVax include University of North Carolina at Chapel Hill, Eno River Capital and Wyeth.

  • Who are AlphaVax's competitors?

    Competitors of AlphaVax include Vaxess Technologies.

Compare AlphaVax to Competitors

V
Vaxxas

Vaxxas is a biotechnology company focused on enhancing the performance of existing vaccines with its nanopatch technology platform. It applies its technology to improve the performance of vaccines, with initial applications targeting infectious disease and oncology. The company was founded in 2011 and is based in Brisbane, Australia.

A
Antigen Express

Antigen Express is a platform and product-based company developing proprietary vaccine formulations for large, unmet medical needs. The company's focus is on stimulating critical members of the immune response, known as T helper cells. The technology allows for antigen-specific stimulation or suppression of a T-helper response to virtually any antigen of known pathogenic potential. Consequentially, Antigen Express is building a deep pipeline of therapeutics aimed at a variety of major diseases, including cancer, infectious diseases and autoimmune-based syndromes.

C
Critical Pharmaceuticals

Critical Pharmaceuticals is an advanced drug delivery company with core expertise in delivery of macromolecules such as DNA, proteins, peptides, siRNA and aptamers.

P
Profectus BioSciences

Profectus Biosciences is a technology based vaccine company devoted to the treatment and prevention of chronic viral diseases. The Company's name, Profectus, when translated from its Latin roots, means"to advance or improve". The Company's proof of concept target is human immunodeficiency virus (HIV) with an intermediate term focus on hepatitis C virus (HCV).

Vaxess Technologies Logo
Vaxess Technologies

Vaxess Technologies is a life science company developing novel vaccine formulations and delivery technologies based on its proprietary silk platform. The company was founded in 2012 and is based in Cambridge, Massachusetts.

Vaxart Logo
Vaxart

Vaxart, formerly Aviragen Therapeutics, Biota Pharmaceuticals, and Nabi Pharmaceuticals, is a clinical-stage company focused on developing oral recombinant protein vaccines based on its proprietary oral vaccine platform and direct-acting antivirals to treat infections that have limited therapeutic options. Vaxart's oral vaccines are designed to generate broad and durable immune responses that protect against a wide range of infectious diseases and may be useful for the treatment of chronic viral infections and cancer. Vaxart's oral vaccines are administered using a convenient room temperature-stable tablet, rather than by injection. Vaxart believes that tablet vaccines are easier to distribute and administer than injectable vaccines, and have the potential to significantly increase vaccination rates. Vaxart's development programs include oral tablet vaccines that are designed to protect against norovirus, seasonal influenza and respiratory syncytial virus (RSV), as well as a therapeutic vaccine for human papillomavirus (HPV). Through the merger, Vaxart also acquired antiviral drug candidates, including teslexivir (BTA074), an antiviral treatment for condyloma caused by HPV types 6 and 11.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.